...
首页> 外文期刊>Open medicine >Integration of human papillomavirus type 16 in cervical cancer cells
【24h】

Integration of human papillomavirus type 16 in cervical cancer cells

机译:人类乳头瘤病毒16型在宫颈癌细胞中的整合

获取原文
获取原文并翻译 | 示例
           

摘要

Cervical cancer remains an important cause of women morbidity and mortality. The progression of cervical pathology correlates with the HPV integration into the host genome. However, the data on the viral integration status in cervical dysplasias are controversial. The aim of the current study was to evaluate the status of HPV integration in two types of cervical pathology - invasive and non invasive cervical cancer (e. g. carcinoma in situ). 156 women were included in the study: 66 women were diagnosed with invasive cervical cancer (CC) and 90 with non invasive cervical cancer (carcinoma in situ, CIS). 74.2% [95% PI: 63.64 divided by 84.76] of specimens collected from women with diagnosed CC and 85.6% [95% PI: 85.53 divided by 92.85] of CIS specimens were positive for HPV. The most prevalent HPV genotype in both groups was HPV16. To evaluate HPV integration, three selected HPV16 E2 gene fragments were analyzed by PCR. In the majority of CC and CIS specimens the amplification of all three HPV16 E2 gene fragments was observed. The episomal HPV16 form was detected in the majority of CC and CIS specimens. The deletion of all three HPV16 E2 gene fragments was detected in 9.4% of CC specimens and 2.2% of CIS specimens. Finally, integration status could not be used as diagnostical additional test to distinguish between invasive and non invasive cervical cancer.
机译:子宫颈癌仍然是妇女发病和死亡的重要原因。宫颈病理学进展与HPV整合入宿主基因组有关。但是,关于宫颈发育不良中病毒整合状态的数据存在争议。当前研究的目的是评估HPV整合在两种类型的子宫颈病理中的状态-浸润性和非浸润性宫颈癌(例如原位癌)。这项研究包括156名妇女:66名妇女被诊断为浸润性宫颈癌(CC),90名妇女被诊断为非浸润性宫颈癌(原位癌,CIS)。从诊断为CC的女性收集的标本中,有74.2%[95%PI:63.64除以84.76]和CIS标本中有85.6%[95%PI:85.53除以92.85]的HPV阳性。两组中最普遍的HPV基因型是HPV16。为了评估HPV整合,通过PCR分析了三个选定的HPV16 E2基因片段。在大多数CC和CIS标本中,观察到所有三个HPV16 E2基因片段的扩增。在大多数CC和CIS标本中检出了游离型HPV16形式。在9.4%的CC标本和2.2%的CIS标本中检测到所有三个HPV16 E2基因片段的缺失。最后,整合状态不能用作诊断浸润性和非浸润性宫颈癌的附加诊断方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号